Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated

References

• Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation - the Framingham Heart Study. Circulation. 2004;110(9):1042–1046.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Freedman B, De Caterina R. et al. Stroke prevention in atrial fibrillation: past, present and future comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230–1239.
   PubMed Web of Science ®Google Scholar
• Ahmad Y, Lip GYH, Lane DA. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can J Cardiol. 2013;29:S4–S13.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip G, Lane D. Stroke prevention in atrial fibrillation patients. Expert Opin Pharmacother. 2010;11:2331–2350.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med. 2007;147(8):590.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Skjøth F, Nielsen PB, et al. Effectiveness and safety of standard-dose nonvitamin k antagonist oral anticoagulants and warfarin among patients With atrial fibrillation with a single stroke risk factor: a Nationwide Cohort Study. Jama Cardiology. 2017;2:872–881.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: asystematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142:1489–1498.
   PubMed Web of Science ®Google Scholar
• Bai Y, Wang YL, Shantsila A. et al. The global burden of atrial fibrillation and stroke a systematic review of the clinical epidemiology of atrial fibrillation in Asia. Chest. 2017;152:810–20.
   PubMed Web of Science ®Google Scholar
• Massaro AR, Lip GYH. Stroke prevention in atrial fibrillation: focus on Latin America. Arq Bras Cardiol. 2016;107:576–8.
   PubMed Web of Science ®Google Scholar
• Chiang C-E, Wang K-L, Lip GYH. Stroke prevention in atrial fibrillation: an Asian perspective. Thromb Haemost. 2014;111:789.
   PubMedGoogle Scholar
• Zubaid M, Rashed WA, Alsheikh-Ali AA. et al. Gulf survey of atrial fibrillation events (gulf safe) design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circulation-Cardiovascular Quality and Outcomes. 2011;4:477–482.
   PubMed Web of Science ®Google Scholar
• Zubaid M, Rashed WA, Alsheikh-Ali AA. et al. Management and 1year outcomes of patients with atrial fibrillation in the Middle East. Angiology. 2015;66:464–471.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Zubaid M, Rashed WA. et al. Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: theGulf SAFE registry. International Journal of Cardiology. 2013;168:1644–1646.
   Google Scholar
• Huisman MV, Ma CS, Diener HC. et al. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation (gloria-af) phase I cohort. Europace. 2016;18:1308–1318.
   PubMed Web of Science ®Google Scholar
• Huisman MV, Rothman KJ, Paquette M. et al. The changing landscape for stroke prevention in Af findings from the GLORIA-AF registry phase 2. J Am Coll Cardiol. 2017;69:777–785.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP. et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: global anticoagulant registry in the FIELD (GARFIELD). American Heart Journal. 2012;163:13–19.e1.
   Google Scholar
• Camm AJ, Accetta G, Al Mahmeed W, et al. Impact of gender on event rates at 1 year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open. 2017;7:e014579.
   Web of Science ®Google Scholar
• Sylvia H, HugoTen C, Gabriele A. et al. Quality of vitamin K antagonist control and 1 year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF Registry. PLoS ONE. 2016 Oct 28;11.
   Google Scholar
• Ajlan M, Almazroa L, AlHabib KF, et al. Atrial fibrillation in patients hospitalized with heart failure: patient characteristics and outcomes from the HEARTS Registry. Angiology. 2017;69:3319717711764.
   Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH. et al. Guidelines for the management of atrial fibrillation (vol 12, pg 1360, 2010). Europace. 2011;13:1118–1126.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GYH, De Caterina R. et al. 2012 focused update of the ESC GUIDELINES for the management of atrial fibrillation an update of the 2010 ESC guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385–1413.
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Sullivan RM, Olshansky B. et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin the SAMe-TT2R2 Score. Chest. 2013;144:1555–1563.
   PubMed Web of Science ®Google Scholar
• Freedman B, Potpara TS, Lip GYH. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806–817.
   PubMed Web of Science ®Google Scholar
• Huang D. The fear of bleeding of new oral anticoagulants (NOAC) is not justified by recent NOAC atrial fibrillation outcome trials. Heart Lung Circ. 2017;26:S302.
   Google Scholar
• Arbelo E, Brugada J, Blomström-Lundqvist C, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in- hospital and 1 year follow- up findings from the ESC- EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017;38:1303–1316.
   PubMed Web of Science ®Google Scholar
• Gage B, Waterman A, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.
   PubMedGoogle Scholar
• Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–272.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Shantsila E, Lane DA. et al. Secondary versus primary stroke prevention in atrial fibrillation insights from the Darlington atrial fibrillation registry. Stroke. 2017;48:2198.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Calkins H. Catheter ablation in patients with persistent atrial fibrillation. Eur Heart J. 2017;38(20).
   Google Scholar
• Raal FJ, Alsheikh-Ali AA, Omar MI. et al. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018;12:76:15.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Rangarajan S, Teo K, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014;371:818–827.
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Omar MI, Raal FJ. et al. Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study. Plos One. 2014;9.
   PubMed Web of Science ®Google Scholar
• Ashburner JM, Go AS, Chang Y. et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. J Am Coll Cardiol. 2016;67:23947.
   Web of Science ®Google Scholar
• Fauchier L, Lecoq C, Clementy N. et al. Oral Anticoagulation and the risk of stroke or death in patients with Atrial Fibrillation and one additional Stroke Risk Factor: the Loire valley Atrial Fibrillation project. Chest. 2016;149:960–968.
   Google Scholar
• Saliba W, Barnett-Griness O, Elias M. et al. Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: a cohort study. Heart rhythm. 2015;12:886–892.
   Google Scholar
• Kundu A. Minimizing the risk of bleeding with NOACs in the elderly. Drugs Aging. 2016;33:491–501.
   PubMed Web of Science ®Google Scholar
• Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J. 2017;38:85259B.
   Google Scholar
• Khan HTA, Hussein S, Deane J. Nexus between demographic change and elderly care need in the Gulf Cooperation Council (GCC) Countries: some policy implications. Ageing Int. 2017;4:466–87.
   Google Scholar
• O’Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388:761–775.
   PubMed Web of Science ®Google Scholar
• Field ME, Page RL. The alivecor heart monitor and microlife watchBP office AFIB for atrial fibrillation screening in a primary care setting. Circulation. 2017;135(12):1120–1122.
   PubMedGoogle Scholar
• Lavie LCJ. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk. Prog Cardiovasc Dis. 2015;58(4):461–462.
   PubMedGoogle Scholar
• Pollack CV, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114:198–205.
   PubMed Web of Science ®Google Scholar
• Thomas MR, Lip GYH. Novel risk markers and risk assessments for cardiovascular disease. Circ Res. 2017;120(1):133–149.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Yanez M, Arias-Rivas S, Santamaria-Cadavid M, et al. High pro- BNP levels predict the occurrence of atrial fibrillation after cryptogenic stroke. Neurology. 2013;81(5):444–447.
   PubMed Web of Science ®Google Scholar
• Shibazaki K, Kimura K, Fujii S, et al. Brain natriuretic Peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol. 2012;109(9):1303–1307.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Oldgren J, Andersson U, et al. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: insights from the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Am Heart J. 2017;190:94–103.
   PubMed Web of Science ®Google Scholar